Jove R - Search Results

1

Multiple Myeloma: New Insights and Therapeutic Approaches.

Anderson KC, Kyle RA, Dalton WS, Landowski T, Shain K, Jove R, Hazlehurst L, Berenson J. Anderson KC, et al. Among authors: jove r. Hematology Am Soc Hematol Educ Program. 2000:147-165. doi: 10.1182/asheducation-2000.1.147. Hematology Am Soc Hematol Educ Program. 2000. PMID: 11701540

2

Drug resistance in multiple myeloma: approaches to circumvention.

Dalton WS, Jove R. Dalton WS, et al. Among authors: jove r. Semin Oncol. 1999 Oct;26(5 Suppl 13):23-7. Semin Oncol. 1999. PMID: 10528891 Review.

3

Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation.

Shain KH, Yarde DN, Meads MB, Huang M, Jove R, Hazlehurst LA, Dalton WS. Shain KH, et al. Among authors: jove r. Cancer Res. 2009 Feb 1;69(3):1009-15. doi: 10.1158/0008-5472.CAN-08-2419. Epub 2009 Jan 20. Cancer Res. 2009. PMID: 19155309 Free PMC article.

4

Inhibition of JAK kinase activity enhances Fas-mediated apoptosis but reduces cytotoxic activity of topoisomerase II inhibitors in U266 myeloma cells.

Oshiro MM, Landowski TH, Catlett-Falcone R, Hazlehurst LA, Huang M, Jove R, Dalton WS. Oshiro MM, et al. Among authors: jove r. Clin Cancer Res. 2001 Dec;7(12):4262-71. Clin Cancer Res. 2001. PMID: 11751528

5

Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells.

Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernández-Luna JL, Nuñez G, Dalton WS, Jove R. Catlett-Falcone R, et al. Among authors: jove r. Immunity. 1999 Jan;10(1):105-15. doi: 10.1016/s1074-7613(00)80011-4. Immunity. 1999. PMID: 10023775 Free article.

6

STAT proteins as novel targets for cancer therapy. Signal transducer an activator of transcription.

Catlett-Falcone R, Dalton WS, Jove R. Catlett-Falcone R, et al. Among authors: jove r. Curr Opin Oncol. 1999 Nov;11(6):490-6. doi: 10.1097/00001622-199911000-00010. Curr Opin Oncol. 1999. PMID: 10550013 Review.

7

Overexpression of a dominant-negative signal transducer and activator of transcription 3 variant in tumor cells leads to production of soluble factors that induce apoptosis and cell cycle arrest.

Niu G, Shain KH, Huang M, Ravi R, Bedi A, Dalton WS, Jove R, Yu H. Niu G, et al. Among authors: jove r. Cancer Res. 2001 Apr 15;61(8):3276-80. Cancer Res. 2001. PMID: 11309279

8

Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells.

Huang M, Dorsey JF, Epling-Burnette PK, Nimmanapalli R, Landowski TH, Mora LB, Niu G, Sinibaldi D, Bai F, Kraker A, Yu H, Moscinski L, Wei S, Djeu J, Dalton WS, Bhalla K, Loughran TP, Wu J, Jove R. Huang M, et al. Among authors: jove r. Oncogene. 2002 Dec 12;21(57):8804-16. doi: 10.1038/sj.onc.1206028. Oncogene. 2002. PMID: 12483533

9

Constitutive RelB activation in v-Src-transformed fibroblasts: requirement for IkappaB degradation.

Shain KH, Jove R, Olashaw NE. Shain KH, et al. Among authors: jove r. J Cell Biochem. 1999 May 1;73(2):237-47. J Cell Biochem. 1999. PMID: 10227387

10

Combination therapy with AG-490 and interleukin 12 achieves greater antitumor effects than either agent alone.

Burdelya L, Catlett-Falcone R, Levitzki A, Cheng F, Mora LB, Sotomayor E, Coppola D, Sun J, Sebti S, Dalton WS, Jove R, Yu H. Burdelya L, et al. Among authors: jove r. Mol Cancer Ther. 2002 Sep;1(11):893-9. Mol Cancer Ther. 2002. PMID: 12481410

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

242 results

Search Page

Filters